Manage Your Liver
Q:

New research finding: New hepatitis C antiviral drugs increase the risk of liver cancer

New research finding: New hepatitis C antiviral drugs increase the risk of liver cancer
A:

A study published in the International Liver Congress in 2016 [1] came up with a shocking and unexpected result: Patients with hepatitis c and cirrhosis who use direct antiviral agents (DAA) may begin to develop liver cancer within 2 weeks. Leading researcher Stefano Brillianti, MD stated “The hypothesis is that immune surveillance may be reduced too rapidly,” and “You have an immediate drop in viremia, but also attenuation of inflammation.”

 

The study indicated that patients with a history of hepatocellular carcinoma (liver cancer) have the highest risk of developing tumor after receiving direct-acting antiviral therapy, in addition, the progression is very fast. "Patients with previous hepatocellular carcinoma are, of course, at risk of recurrence anyway," Dr Brillianti said. ”A 30% rate over 3 years from initial surgery or ablation is normal. What was surprising to us was that we were observing 4 cm lesions after 12 weeks." [2]

 

Another research conducted by the University of Barcelona found that out of 58 hepatitis C patients with a history of hepatocellular carcinoma (with complete radiologic response), 55 were cirrhotic before starting direct-acting antiviral therapy. After a median follow-up of 5.7 months, the rate of tumor recurrence was 27.6%, with a median time to recurrence of 3.5 months. This research echoes with the previously mentioned, and suggests that patients with hepatitis C should be closely monitored after treatment with direct-acting antivirals. [3]

 

Stefano Brillanti, MD, went on to say, "This (liver cancer) is a different cancer  than elsewhere in oncology — it is a cancer within an advanced chronic disease — so the prognosis, the life expectancy, is related not only to the liver cancer but also to the liver disease and liver function,”. He added, "If you don't treat these patients and ameliorate their liver function, and if hepatocellular carcinoma occurs, you have no chance of curing them. But if you ameliorate liver function and they develop hepatocellular carcinoma, you can cure it better because their improved liver function will allow an ablation.”

 

These two latest research studies once again prove that is it vital to stop inflammation in the liver, and to ensure normal liver function. Whether it is before or after treatment, both hepatitis C patients and patients with hepatocellular carcinoma history should set this as their main objective. Otherwise, even if the virus is successfully removed from the body, normal liver function cannot be guaranteed.

Disclaimer:
  • * All research and clinical data should be used as reference purposes only, results may vary.
Related Questions
A:
About 2.7 million persons in the United States are infected with hepatitis C virus in their blood. The majority of these individuals remain asymptomatic for many years following the initial infection, and many people can even live their whole life with hepatitis C virus in their body without knowing they are infected. On the other hand, some carriers will develop chronic hepatitis C, meaning that the virus in their body attacks the liver, causing liver damage with elevated alan
A:
Since the introduction of direct-acting antiviral (DAA) therapy, treatment for hepatitis C (HCV) was revolutionized, as patient outcomes are improved with fewer side effects and high cure rate. However, there is significant debate in the society based on studies that suggest HCV cure does not eliminate risk for hepatocellular carcinoma (HCC) or liver cancer. Other research suggests the possibility of increased risk of developing liver cancer during and after DAA treatment in patients with hep
Hit Questions
A:
Hepatitis C is a wide spread and deadly disease affecting an estimated of 3.5 million Americans.   Treatment for hepatitis C has evolved over the years, going from highly toxic drugs involving injections with horrible side effects, to medications with minimal side effects. Success rate of treatment options has also improved greatly Although the high price tag of the new DAA treatment is controversial, it has undoubtedly helped to cure many hepatitis C patients.
A:
Fibrosis is scarring of the liver that results from chronic inflammation. It is a process where the damaged, dying liver cells are replaced by fibrous scar tissue, causing the liver to become hard. The extent of liver fibrosis can vary, and it is often classified in several stages. The most common classification is a scale from F0 to F4. F0 indicates no fibrosis. A normal liver is at a stage between F0 and F1. F2 denotes light fibrosis, and F3 indicates severe fibrosis. When scar tissue build
A:
You probably have already heard about the new antiviral hep C drug, which is effective but insanely expensive. It claims to have around 90% success rate, that’s why so many hepatitis C patients are dying for it even though it’s extremely costly. But apart from its expensive price tag, there is a bigger issue behind this new drug that not many people know about. Scientists and researchers have found an increased risk of extreme liver cancer related to this new drug after successful
A:
Hepatitis C viruses share a common characteristic to other chronic liver diseases; it could damage the patients’ liver cells. Hepatitis C patients should focus on stopping or reducing the damage in the liver, and this focus should be the same for other chronic liver diseases e.g. hepatitis B, fatty liver disease, NASH etc. And this is exactly what YHK can do.   YHK can stop liver cells damage caused by hepatitis viruses, and can repair damaged liver cells, to he
YHK Liver Therapy
Your Liver
Protection

starts here.
Buy YHK
Have Questions?
Sumbit your question to us for profeessional answers!
Looking for help? Ask our customer support team!
Contact Us